Download - ASCO2024 special: Circulating kidney injury molecule-1 biomarker analysis in IMmotion010

Discover

Podcast Features
Your all-in-one podcasting solution.

Blog to Podcast
Turn your blog into an engaging podcast.
Livestream
High-performing audio live, without limits.

Podcast Studio
Easy-to-use audio recorder app.
Podbean AI
AI-Enhanced Audio Quality and Content Generation.

Podcast App
The best podcast player & podcast app.

Ads Marketplace
Join Ads Marketplace to earn money
through sponsorship on your podcast.

PodAds
Manage your ads with dynamic ad insertion capability.
Apple Podcasts Subscriptions Integration
Effortlessly publish and manage exclusive episodes for your
Apple Podcasts subscribers directly from Podbean.
Live Streaming
Receive livestream rewards from your audience and earn
recurring income from your Fan Club membership.

All Arts Business Comedy Education
Fiction Government Health & Fitness History Kids & Family
Leisure Music News Religion & Spirituality Science
Society & Culture Sports Technology True Crime TV & Film
Live

How to Start a Podcast
How to Start a Live Podcast
How to Monetize a podcast
How to Promote Your Podcast
How to Use Group Recording

Log in
Start your podcast for free

Podcasting
Monetization
Advertisers
Enterprise
Pricing
Discover

EAU Podcasts

Education

ASCO2024 special: Circulating kidney injury molecule-1 biomarker analysis in IMmotion010

2024-06-15

Download Right click and do "save link as"

In this podcast, UROONCO RCC chief editor Dr. Maria Carmen Mir (ES) talks to Prof. Laurence Albiges (FR) on the abstract she recently presented at ASCO2024 - “Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomised phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection”.

Prof. Albiges details the two parts of the circulating biomarker analysis scheme, part one - biomarker identification/screening; and part two - assessing the association of circulating kidney injury molecule-1 with disease free survival outcomes.

The study results are discussed in detail and Prof. Albiges talks about what research is needed in the future to confirm the utility of circulating serum kidney injury molecule-1 in adjuvant RCC as a non-invasive biomarker.